Sanofi-a Ventis Deutschland Gmbh

Sanofi

Carolina Lanter

Stephanie Hachtel

Stephen J Shimshock

Juergen Dedio

Raymond W Kosley, Jr

Siegfried Stengelin

Kenneth J Bordeau

Matthias Gossel

Josef Pernerstorfer

Holger Heitsch

Thomas Klabunde

Gregory H Merriman

Werngard Czechtizky

Brian K Whiteley

Martin Smrcina

Pavel Safar

Aleksandra Weichsel

Rosy Sher

Sven Grueneberg

James Spoonamore

Joseph T Klein

Hui Li

Zhaoxia Yang

Stefanie Flohr

Petra Lennig

Petra Stahl

Raymond Kosley

Stephen Shimshock

Jürgen Dedio

Hui Sanofi-Aventis Us Inc Li

Stephen Sanofi-Aventis Us Inc Shimshock

The invention relates to compounds of the formula I in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

CXCR2 inhibitors

CXCR2 antagonists

The invention relates to compounds of the formula I in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Inhibitors of CXCR2

The invention relates to compounds of the formula I: in which R1, R2, X, A, B, D and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.

Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids

Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.

Nitrogen-substituted hexahydropyrazino[1,2-A]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments

Growing community of inventors

Audubon, PA, United States of America

Carolina Lanter